TCT 2017

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

We Recommend